Comparison of Local Methylcobalamin and Subcutaneous Lidocaine in Subacute Herpetic Neuralgia
Comparison of Local Methylcobalamin Injection Versus Subcutaneous Lidocaine Injection in Patients With Subacute Herpetic Neuralgia
This randomized controlled trial will compare methylcobalamin and lidocaine injections for pain relief in 60 patients with subacute herpetic neuralgia over four weeks.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This randomized controlled trial will compare the efficacy of local subcutaneous methylcobalamin injection versus subcutaneous lidocaine injection in patients aged 40-70 years with unilateral subacute herpetic neuralgia and baseline pain score greater than 6 on the visual analogue scale (VAS). A total of 60 patients will be randomly allocated to two groups, with 30 patients in each group. Group A will receive methylcobalamin injection (1 mg/2 mL), while Group B will receive lidocaine injection (1%, 2 mL), six times per week for four weeks. Pain intensity and sleep disturbance will be assessed at baseline and after 28 days of treatment. Treatment efficacy will be defined as a pain score below 3 at the end of treatment. Adverse effects will also be monitored and recorded. The study will be conducted at the Department of Dermatology, Combined Military Hospital (CMH), Multan, over six months following synopsis approval.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Punjab Province
-
Multan, Punjab Province, Pakistan, 60000
- Rekruttering
- Cmh Multan
-
Kontakt:
- HIJAB Fatima, MBBS
- Telefonnummer: +923359076219
- E-mail: hijab.fatimahf7@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
>Inclusion Criteria:
- Patients aged 40-70 years, male or female.
- Unilateral subacute herpetic neuralgia, defined as dermatomal neuropathic pain more than 30 days and up to 90 days after rash onset.
- Baseline pain score greater than 6 on the Visual Analogue Scale (VAS).
Exclusion Criteria:
- Diffuse neuropathic pain extending beyond the affected dermatome.
- Cognitive impairment.
- Use of topical agents or nerve-blocking agents within 10 days before enrolment.
- Immunocompromised patients receiving steroids at a dose of 2 mg/kg/day for more than 14 days or undergoing chemotherapy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Methylcobalamin Injection Group
Participants will receive local subcutaneous methylcobalamin injection (1 mg/2 mL), six times per week for four weeks. |
Methylcobalamin injection (1 mg/2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks. |
|
Aktiv komparator: Lidocaine Injection Group
Participants will receive local subcutaneous lidocaine injection (1%, 2 mL), administered six times per week for four weeks. |
Lidocaine inLidocaine injection (1%, 2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain score
Tidsramme: Baseline (Day 1) and Day 28 (end of treatment).
|
Change in pain intensity measured using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (maximum bearable pain). Treatment efficacy is defined as a pain score below 3 at 28 days after randomization. |
Baseline (Day 1) and Day 28 (end of treatment).
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sleep Disturbance Score
Tidsramme: Baseline (Day 1) and Day 28 (end of treatment).
|
Sleep disturbance assessed using a numeric rating scale ranging from 0 (no disturbance) to 10 (severe disturbance). |
Baseline (Day 1) and Day 28 (end of treatment).
|
|
Adverse Effects
Tidsramme: Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.
|
Assessment and recording of adverse effects, including redness, swelling, hematoma formation, dizziness, and urticaria following injections. |
Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022 Jan 19;14(2):192. doi: 10.3390/v14020192.
- Ramadhani A, Astuti I, Widiastuti MG, Purwanti N. Methylcobalamin as a candidate for chronic peripheral neuropathic pain therapy: review of molecular pharmacology actiona. Korean J Pain. 2024 Oct 1;37(4):299-309. doi: 10.3344/kjp.24171.
- Xu G, Lv ZW, Feng Y, Tang WZ, Xu GX. A single-center randomized controlled trial of local methylcobalamin injection for subacute herpetic neuralgia. Pain Med. 2013 Jun;14(6):884-94. doi: 10.1111/pme.12081. Epub 2013 Apr 8.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- File no 13/Trg--ERC No 132/26
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .